Compare e l f Beauty Inc (ELF) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Gilead Sciences, Inc. — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.20B), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 29.4× e l f Beauty Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Gilead Sciences, Inc. for 111 Days on average.
| ELF | GILD | |
|---|---|---|
Market Cap | $6.20B | $182.09B |
Volume | 1,301,240 | 4,960,247 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $155.80 |
52-Week Low | $49.57 | $116.74 |
Typical Hold Time | 25 Days | 111 Days |
Enterprise Value | $6.78B | $205.15B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
